{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:36:52Z","timestamp":1780461412214,"version":"3.54.1"},"reference-count":34,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T00:00:00Z","timestamp":1666569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Chemotherapy-induced febrile neutropenia is the most widespread oncologic emergency with high morbidity and mortality rates. Herein we present a retrospective risk factor identification study to evaluate the prognostic role of lymphocyte-based measures and ratios in a cohort of chemotherapy-induced febrile neutropenia patients following granulocyte colony-stimulating factor (G-CSF) therapy. Materials and Methods: The electronic medical records at our center were utilized to identify patients with a first attack of chemotherapy-induced febrile neutropenia and were treated accordingly with G-CSF between January 2010 to December 2020. Patients\u2019 demographics and disease characteristics along with laboratory tests data were extracted. Prognosis-related indicators were the absolute neutrophil count (ANC) at admission and the following 6 days besides the length of stay and mortality rate. Results: A total of 80 patients were enrolled, which were divided according to the absolute lymphocyte count at admission into two groups, the first includes lymphopenia patients (n = 55) and the other is the non-lymphopenia group (n = 25) with a cutoff point of 700\u2009lymphocytes\/\u03bcL. Demographics and baseline characteristics were generally insignificant among the two groups but the white blood cell count was higher in the non-lymphopenia group. ANC, neutrophils percentage and ANC difference in reference to admission among the two study groups were totally insignificant. The same insignificant pattern was observed in the length of stay and the mortality rate. Univariate analysis utilizing the ANC difference compared to the admission day as the dependent variable, revealed no predictability role in the first three days of follow up for any of the variables included. However, during the fourth day of follow up, both WBC (OR = 0.261; 95% CI: 0.075, 0.908; p = 0.035) and lymphocyte percentage (OR = 1.074; 95% CI: 1.012, 1.141; p = 0.019) were marginally significant, in which increasing WBC was associated with a reduction in the likelihood of ANC count increase, compared to the lymphocyte percentage which exhibited an increase in the likelihood. In comparison, sequential ANC difference models demonstrated lymphocyte percentage (OR = 0.961; 95% CI: 0.932, 0.991; p = 0.011) and monocyte-to-lymphocyte ratio (OR = 7.436; 95% CI: 1.024, 54.020; p = 0.047) reduction and increment in the enhancement of ANC levels, respectively. The fifth day had WBC (OR = 0.790; 95% CI: 0.675, 0.925; p = 0.003) to be significantly decreasing the likelihood of ANC increment. Conclusions: we were unable to determine any concrete prognostic role of lymphocyte-related measures and ratios. It is plausible that several limitations could have influenced the results obtained, but as far as our analysis is concerned ALC role as a predictive factor for ANC changes remains questionable.<\/jats:p>","DOI":"10.3390\/medicina58111508","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T06:37:45Z","timestamp":1666593465000},"page":"1508","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Prognostic Utility of Lymphocyte-Based Measures and Ratios in Chemotherapy-Induced Febrile Neutropenia Patients following Granulocyte Colony-Stimulating Factor Therapy"],"prefix":"10.3390","volume":"58","author":[{"given":"Omar M.","family":"Halalsheh","sequence":"first","affiliation":[{"name":"Division of Urology, Department of General Surgery and Urology, Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan O.","family":"Al Zu\u2019bi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed H.","family":"Al Sharie","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0408-2600","authenticated-orcid":false,"given":"Farouk H.","family":"Wafai","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3258-8083","authenticated-orcid":false,"given":"Nadeem","family":"Alabdallah","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumana","family":"AlSeidi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia A.","family":"Hussein","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majd N.","family":"Daoud","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abubaker A.","family":"Malkawi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5564-4925","authenticated-orcid":false,"given":"Ahmad O.","family":"Alomari","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Alshari","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.critrevonc.2010.03.008","article-title":"Febrile neutropenia: A critical review of the initial management","volume":"78","author":"Klastersky","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4049\/jimmunol.1500861","article-title":"G-CSF and GM-CSF in Neutropenia","volume":"195","author":"Mehta","year":"2015","journal-title":"J. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s11899-013-0171-4","article-title":"Febrile neutropenia in hematologic malignancies","volume":"8","author":"Keng","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"v252","DOI":"10.1093\/annonc\/mdq196","article-title":"Management of febrile neutropenia: ESMO Clinical Practice Guidelines","volume":"21","author":"Gill","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"8291316","DOI":"10.1155\/2017\/8291316","article-title":"Cytokine Kinetics in Febrile Neutropenic Children: Insights on the Usefulness as Sepsis Biomarkers, Influence of Filgrastim, and Behavior of the IL-23\/IL-17 Pathway","volume":"2017","author":"Araujo","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1086\/598621","article-title":"Contemporary Antimicrobial Susceptibility Patterns of Bacterial Pathogens Commonly Associated with Febrile Patients with Neutropenia","volume":"29","author":"Jones","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s101560170027","article-title":"Management of fever in neutropenic patients","volume":"7","author":"Bodey","year":"2001","journal-title":"J. Infect. Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JOP.18.00269","article-title":"Optimal Management of Neutropenic Fever in Patients With Cancer","volume":"15","author":"Zimmer","year":"2019","journal-title":"J. Oncol. Pr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.hoc.2017.08.004","article-title":"Neutropenic Fever","volume":"31","author":"White","year":"2017","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1007\/s00520-015-2686-9","article-title":"The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: A systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Wang","year":"2015","journal-title":"Support Care Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.1007\/s00520-021-06266-x","article-title":"Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma","volume":"29","author":"Cerchione","year":"2021","journal-title":"Support Care Cancer"},{"key":"ref_12","first-page":"963","article-title":"Evaluating the Prognostic Role of Monocytopenia in Chemotherapy-Induced Febrile Neutropenia Patients Treated with Granulocyte Colony-Stimulating Factor","volume":"17","author":"Alshari","year":"2021","journal-title":"Clin. Risk Manag."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","article-title":"Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review","volume":"90","author":"Lyman","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1200\/JOP.2016.019588","article-title":"Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012","volume":"13","author":"Tai","year":"2017","journal-title":"J. Oncol. Pr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1093\/annonc\/mdr520","article-title":"Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre","volume":"23","author":"Schelenz","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3892\/mco.2015.524","article-title":"Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study","volume":"3","year":"2015","journal-title":"Mol. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"104140","DOI":"10.1016\/j.ijmedinf.2020.104140","article-title":"Predicting in-hospital mortality of patients with febrile neutropenia using machine learning models","volume":"139","author":"Du","year":"2020","journal-title":"Int. J. Med. Inf."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Baertl, S., Walter, N., Engelstaedter, U., Ehrenschwender, M., Hitzenbichler, F., Alt, V., and Rupp, M. (2022). What Is the Most Effective Empirical Antibiotic Treatment for Early, Delayed, and Late Fracture-Related Infections?. Antibiotics, 11.","DOI":"10.3390\/antibiotics11030287"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/cncr.20983","article-title":"Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy","volume":"103","author":"Caggiano","year":"2005","journal-title":"Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1200\/JCO.2007.13.8222","article-title":"Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia","volume":"26","author":"Elting","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_22","first-page":"2561","article-title":"The medical course of cancer patients with fever and neutropenia","volume":"148","author":"Talcott","year":"1988","journal-title":"Clin. Identif. Low Risk Subgr. Present. Arch. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","article-title":"The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients","volume":"18","author":"Klastersky","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00520-004-0614-5","article-title":"Febrile neutropenia: A prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score","volume":"12","author":"Uys","year":"2004","journal-title":"Support Care Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1200\/JCO.2014.57.2347","article-title":"Prediction of serious complications in patients with seemingly stable febrile neutropenia: Validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study","volume":"33","author":"Antonio","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1200\/JCO.1996.14.2.636","article-title":"Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia","volume":"14","author":"Blay","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/annonc\/mdn560","article-title":"Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer","volume":"20","author":"Jenkins","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.bjc.6600724","article-title":"Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy","volume":"88","author":"Borg","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s00520-019-04946-3","article-title":"Predictive value of monocytes and lymphocytes for short-term neutrophil changes in chemotherapy-induced severe neutropenia in solid tumors","volume":"28","author":"Zheng","year":"2020","journal-title":"Support Care Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Chen, K., Zhang, X., Deng, H., Zhu, L., Su, F., Jia, W., and Deng, X. (2014). Clinical Predictive Models for Chemotherapy-Induced Febrile Neutropenia in Breast Cancer Patients: A Validation Study. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096413"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.31557\/apjcb.2020.5.3.81-87","article-title":"Pretreatment Absolute Neutrophil-to-Lymphocyte Ratio (NLR) Predict the Risk for Febrile Neutropenia in the First Cycle Adjuvant Chemotherapy for Breast Cancer","volume":"5","author":"Chantharakhit","year":"2020","journal-title":"Asian Pac. J. Cancer Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/SHK.0000000000001256","article-title":"Platelet-lymphocyte Ratio After Granulocyte Colony Stimulating Factor Administration: An Early Prognostic Marker in Septic Shock Patients With Chemotherapy-Induced Febrile Neutropenia","volume":"52","author":"Kim","year":"2019","journal-title":"Shock"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/14653240310000047","article-title":"Efficacy of granulocyte transfusions for neutropenia-related infections: Retrospective analysis of predictive factors","volume":"5","author":"Rutella","year":"2003","journal-title":"Cytotherapy"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur. J. Cancer"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/11\/1508\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:01:30Z","timestamp":1760144490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/11\/1508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,24]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["medicina58111508"],"URL":"https:\/\/doi.org\/10.3390\/medicina58111508","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,24]]}}}